 | |
| Clinical data | |
|---|---|
| Trade names | Rescula |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| Routes of administration | Topical (eye drops) |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Eliminationhalf-life | 14 min |
| Excretion | Renal |
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.227.145 |
| Chemical and physical data | |
| Formula | C22H38O5 |
| Molar mass | 382.541 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Unoprostone (INN) is aprostaglandin analogue. Itsisopropylester,unoprostone isopropyl, was marketed under the trade nameRescula for the management ofopen-angle glaucoma andocular hypertension.[1][2]
It was approved by theFood and Drug Administration in 2000.[3]
In 2009,Sucampo Pharmaceuticals acquired the rights to the drug in the U.S. and Canada.[4]
In 2015, the drug was discontinued in the U.S.[citation needed]
 | Thispharmacology-related article is astub. You can help Wikipedia byexpanding it. |